Form EFFECT BioLineRx Ltd.
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 2, 2026 4:30 P.M. |
| Form: | F-1 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ANCEL Survey: 95.2% of Super Starter Users Report Improved Vehicle Starting Performance
- Hidradenitis Suppurativa Market Set for Robust Expansion at a rapid CAGR Through 2036: Key Drivers, Trends, and Leading Players | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Bio
- Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share